Ines Zugasti
Overview
Explore the profile of Ines Zugasti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
13
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jimenez-Vicente C, Arribas I, Pomares H, Ramil G, Castano-Diez S, Perez-Valencia A, et al.
Haematologica
. 2025 Jan;
PMID: 39844754
Not available.
2.
Alamo J, Mont-de Torres L, Castano-Diez S, Mensa-Vilaro A, Monica Lopez-Guerra M, Zugasti I, et al.
Br J Haematol
. 2025 Jan;
206(2):565-575.
PMID: 39806534
VEXAS syndrome is a haemato-inflammatory disease caused by somatic UBA1 mutations and characterized by cytoplasmic vacuoles in myeloid and erythroid precursor cells. Although there is currently no standard treatment algorithm...
3.
Martinez-Roca A, Jimenez-Vicente C, Merchan B, Castano-Diez S, Zugasti I, Brillembourg H, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766173
Even though venetoclax in combination with azacitidine (VenAza) is considered a low-intensity regimen, its patients present a high incidence of cytopenia and infections during the first courses, making the initial...
4.
Safi R, Mohsen-Kanson T, Kouzi F, El-Saghir J, Dermesrobian V, Zugasti I, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682159
Background/objectives: A specialized microenvironment in the bone marrow, composed of stromal cells including mesenchymal stem cells (MSCs), supports hematopoietic stem cell (HSC) self-renewal, and differentiation bands play an important role...
5.
Zugasti I, Tormo-Ratera M, Oliver-Caldes A, Soler-Perromat J, Gonzalez-Calle V, Moreno D, et al.
Blood Adv
. 2024 Nov;
9(3):571-582.
PMID: 39602341
Multiple myeloma (MM) remains incurable, with poor outcomes in heavily pretreated patients. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment; however, outcomes after such therapy in...
6.
Castano-Diez S, Lopez-Guerra M, Zugasti I, Calvo X, Schulz F, Avendano A, et al.
Blood Adv
. 2024 Oct;
9(1):39-53.
PMID: 39388660
Mutations commonly associated with acute myeloid leukemia (AML), such as CEBPA, FLT3, IDH1/2, and NPM1, are rarely found in chronic myelomonocytic leukemia (CMML), and their prognostic significance in CMML has...
7.
Castano-Diez S, Alamo J, Lopez-Guerra M, Gomez-Hernando M, Zugasti I, Jimenez-Vicente C, et al.
Oncologist
. 2024 Sep;
30(2).
PMID: 39349391
The 2022 WHO revision and the ICC classification have recently modified the diagnostic criteria for chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia. However, there is no consensus on whether...
8.
Jimenez-Vicente C, Guardia-Torrelles A, Perez-Valencia A, Martinez-Roca A, Castano-Diez S, Guijarro F, et al.
Ann Hematol
. 2024 Aug;
103(10):4033-4043.
PMID: 39207559
Although there is an approved indication for venetoclax and hypomethylating agents (VenHMA) and its use in different AML settings will be expanded in the following years, the management of the...
9.
de Landazuri I, Oliver-Caldes A, Espanol-Rego M, Agullo C, Contreras M, Zabaleta A, et al.
Br J Haematol
. 2024 Jun;
205(4):1346-1355.
PMID: 38894496
Chimeric antigen receptor (CAR) T-cell therapies have increased the patients with relapsed/refractory multiple myeloma (RRMM) in whom standard electrophoretic techniques fail to detect the M-protein. Quantitative immunoprecipitation mass spectrometry (QIP-MS)...
10.
Zugasti I, Guardia A, Jorda-Sanchez R, Cuartas-Gonzalez A, Nomdedeu M, Arellano-Rodrigo E
Emergencias
. 2024 May;
36(3):228-230.
PMID: 38818989
No abstract available.